This Readme_Meng_Tumor_Model.txt file was generated on <20200521> by <Fanben Meng>


-------------------
GENERAL INFORMATION
-------------------


1. Title of Dataset 
	Supporting data for "3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments"

2. Author Information


  Principal Investigator Contact Information
           Name: Angela Panoskaltsis-Mortari
           Institution: Univerisy of Minnesota
           Address: Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
           Email: panos001@umn.edu 
	   ORCID: 0000-0003-1802-1785

  Principal Investigator Contact Information
           Name: Michael C. McAlpine
           Institution: Univerisy of Minnesota
           Address: Department of Mechanical Engineering, University of Minnesota, Minneapolis, MN 55455, USA
           Email: mcalpine@umn.edu 
	   ORCID: 0000-0001-7869-7598

  Associate or Co-investigator Contact Information
           Name: Fanben Meng
           Institution: Univerisy of Minnesota
           Address: Department of Mechanical Engineering, University of Minnesota, Minneapolis, MN 55455, USA
           Email: fmeng@umn.edu
	   ORCID: 0000-0002-3309-2568

  Associate or Co-investigator Contact Information
           Name: Carolyn M. Meyer
           Institution: Univerisy of Minnesota
           Address: Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
           Email: meyer167@umn.edu
	   
  Associate or Co-investigator Contact Information
           Name: Daeha Joung
           Institution: Virginia Commonwealth University
           Address: Department of Physics, Virginia Commonwealth University, Richmond, VA 23284, USA
           Email: joungd2@vcu.edu
	   ORCID: 0000-0002-1016-9374

  Associate or Co-investigator Contact Information
           Name: Daniel A. Vallera
           Institution: Univerisy of Minnesota
           Address: Department of Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
           Email: valle001@umn.edu
	   ORCID: 0000-0003-4587-3238

3. Date of data collection (single date, range, approximate date) <suggested format YYYYMMDD>
	Approximate date: 20170101 - 20181201

4. Geographic location of data collection (where was data collected?): 
	University of Minnesota

5. Information about funding sources that supported the collection of the data:
	National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (Award No. 1R21EB022830)
	A seed grant from the UMN Institute for Engineering in Medicine
	A Pilot Project award from the UMN Prostate and Urologic Cancer Translational Workgroup
	National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (Award No. 1DP2EB020537)
	Cancer Bioengineering Fellowship from Physical Sciences in Oncology Center (PSOC) at the UMN




--------------------------
SHARING/ACCESS INFORMATION
-------------------------- 


1. Licenses/restrictions placed on the data:
	CC BY-NC 3.0 US
	https://creativecommons.org/licenses/by-nc/3.0/us/

2. Links to publications that cite or use the data:
	https://onlinelibrary.wiley.com/doi/abs/10.1002/adma.201806899

3. Links to other publicly accessible locations of the data:
	NA

4. Links/relationships to ancillary data sets:
	NA

5. Was data derived from another source?
        No

6. Recommended citation for the data:
	Meng, Fanben; Meyer, Carolyn M.; Joung, Daeha; Vallera, Daniel A.; McAlpine, Michael C.; Panoskaltsis-Mortari, Angela (2020). Supporting data for "3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments". Retrieved from the Data Repository for the University of Minnesota.
	


---------------------
DATA & FILE OVERVIEW
---------------------
All the .opj files were generated using OriginPro 8.1.
Code files (Excel) were created to program Fisnar F5200N gantry robot via Smart Robot.

1. File List
   A. Filename: Data 1_Supporting Data for Growth Factor Release.zip        
      Short description: Supporting data files for Figure 1c, 1e and S1c      
        
   B. Filename: Data 2_Supporting Data for Guided Tumor Cell Migration.zip       
      Short description: Supporting data files for Figure 2d-f and S2c  
        
   C. Filename: Data 3_Supporting Data for Cell Viability.zip     
      Short description: Supporting data files for Figure S3

   D. Filename: Data 4_Supporting Data for qPCR.zip    
      Short description: Supporting data files for Figure 3f, 3h and S5
        
   E. Filename: Data 5_Supporting Data for Drug Tests.zip 
      Short description: Supporting data files for Figure 4b-d, S8 and S9c
       
   F. Filename: Printing Code & Chamber Design - Fisnar.zip
      Short description: Code files (excel format) for Smart Robot (Softare of Fisnar F5200N). 
      "chamber printing program-migration" prints Fig 2b and Fig S1b 
      "chamber printing program-modelX2" prints chambers for Fig 3a and Fig S7



2. Are there multiple versions of the dataset? yes/no
	No


3. Description of figures

1c: Plots showing release of EGF from a bare core (blue), a ruptured capsule (red) and a nonruptured capsule (black), demonstrating the capability of temporal control over the payload release (100% was defined by the intensity of a blank capsule in the absence of Texas Red-labeled EGF, mean ± standard deviation (s.d.), n = 6 per group).

1e: Plots of EGF concentration measured in chambers I (3 mm to the EGF capsule, red) and II (9 mm to the EGF capsule, black) versus time, showing a gradient generated via laser-triggered release of an EGF capsule (mean ± s.d., n = 4 per group; inset: schematic images showing the relative positions between the capsule and chambers). Scale bar: 500 µm 

2d: Plots of cellular fluorescence intensity of A549s (normalized by intensity at day 0 before capsules were ruptured) versus time with (red) and without (black) EGF release, demonstrating the influence of EGF to cellular proliferation (mean ± s.d., n = 4 per group). 

2e: Plots of the displacement of leading A549 cells (only the distance in the x ‐direction was measured) toward the EGF capsule direction (red) and control capsule direction (black) (mean ± s.d., n = 4 per group). 

2f: Bar chart of distributions of GFP–A549s (red), GFP–M4A4s (blue), and RFP–HUVECs (gray) on day 10, showing the selective directed migration of tumor cells but not HUVECs (mean ± s.d., n = 4 per group). Scale bar: 500 µm

3f: Bar chart showing the expression of EGF, VEGF, EGFR, and VEGFR of A549s (upper panel) and HUVECs (lower panel) when mono cell-cultured (gray) and co‐cell‐cultured without (blue) and with (red) EGF and VEGF within fibrin gels (normalized by the levels of each mono cell-cultured samples, mean ± s.d., n = 3 per group, N.D.: nondetectable).

3h: red channel: RFP-expressing HUVECs). h) Plots of the population of disseminated A549s detected in the collection chamber versus time. (mean ± s.d., n = 3 per group) 

4b: Plots of cellular fluorescence intensity of A549s (normalized by intensity at day 0 before immunotoxins were added) versus time without (black) and with treatment of toxins (red: target, blue: off-target), demonstrating the effect of drugs on cell viability (mean ± s.d., red: n = 5, blue and black: n = 3 on each day).

4c: Bar graph comparing the anticancer effect of immunotoxins over time, showing the drug screening application of the model (mean ± s.d., red: n = 5; blue: n = 3 on each day; *p < 0.05, day 3: p = 0.002, day 6: p = 0.025, day 9: p = 0.023, unpaired, two-tailed Student's t -test).

4d: Plots of relative cell viability (calculated by the ratio between the fluorescence intensity of treated models and parallel negative controls) of A549s versus time, showing the influence of the microenvironment on drug screening (mean ± s.d., red and black: n = 5, blue; n = 3 on each day). Scale bar: 500 µm

S1c:  Plot of EGF concentration difference between chamber I and chamber II vs time, after laser-triggered rupture of an EGF capsule, showing that an EGF gradient was generated and maintained for a 2-day period (mean ± s.d., n=4 per group)

S2c: ) Tumor cell migration tracking: plots quantitatively showing the positions of A549s and printed capsules in a coordinate system on days 0, 2, 4, 6, 8, and 10 (red dots: A549s, blue circles: EGF capsules, black circles: control capsules without growth factor payload, cross lines: laser pathways).

Figure S3: Viability of cells for the tumor model fabrication. Bar charts showing the cell viability of a) HUVECs before (gray) and after (red) injection, and b) A549s before (gray) and after (red) 3D bioprinting through 32-gauge nozzles. 

Figure S5: Growth factor and receptor expression in M4A4s/HUVECs. Bar chart showing the expressions of EGF, VEGF, EGFR and VEGFR of M4A4s (upper panel) and HUVECs (lower panel) when mono cell-cultured (gray) and co-cell-cultured without (blue) and with (red) EGF and VEGF within fibrin gels (normalized by the levels of each mono-cell cultured samples, mean ± s.d., n=3 per group, N.D.: non-detectable).

Figure S8: Effect of immunotoxins. a) Plots of the displacement of leading A549 cells (toward the EGF capsule direction, only the distance in the x-direction was measured) vs   time without (black) and with treatment of toxins (red: target, blue: off-target), demonstrating the effect of drugs on tumor cell invasion (mean ± s.d., red: n=5, blue and black: n=3 on each day). b) Bar graph showing no influence of either immunotoxin EGF4KDEL or CD22KDEL on HUVEC cell viability (mean ± s.d., red: n=5, blue: n=3, *p > 0.05, p = 0.64, unpaired, two-tailed Student’s t test).

S9c: Plots of cellular fluorescence intensity of A549s (normalized to intensity at day 0 before addition of immunotoxin) vs   time within fibroblast-laden models (solid symbols) and fibroblast-free models (blank symbols), with (red) and without (black) toxin treatment, demonstrating the influence of the incorporation of fibroblasts on the effect of the drug (mean ± s.d., fibroblasts+: n=5 per group, fibroblasts-: n=3 per group).